Corvus Pharmaceuticals, Inc.
US ˙ NasdaqGM ˙ US2210151005

Introduktion

Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Terry P Gould. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.

Gennemsnitlig handelsrentabilitet

Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.

Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.

Opdateringsfrekvens: Dagligt

Se listen over de mest profitable insiderhandlere.

Virksomheder med rapporterede insider-stillinger

SEC-registreringen viser, at Terry P Gould har rapporteret besiddelser eller handler i følgende virksomheder:

Sikkerhed Titel Senest indberettede beholdninger
US:APTX / Aptinyx Inc. Director 40.000
US:CRVS / Corvus Pharmaceuticals, Inc. Director, 10% Owner 15.000
US:ICVX / Icosavax, Inc. Director 0
US:OMED / OptMed Inc Director 15.000
Sådan fortolkes diagrammerne

Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Terry P Gould. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.

I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.

Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.

Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.

Insiderkøb CRVS / Corvus Pharmaceuticals, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CRVS / Corvus Pharmaceuticals, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

CRVS / Corvus Pharmaceuticals, Inc. Insider Trades
Insidersalg CRVS / Corvus Pharmaceuticals, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CRVS / Corvus Pharmaceuticals, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

CRVS / Corvus Pharmaceuticals, Inc. Insider Trades
Insiderhandelshistorie

Denne tabel viser den komplette liste over insiderhandler foretaget af Terry P Gould som oplyst til Securities Exchange Commission (SEC).

Fil dato Transdato Form Ticker Sikkerhed Kode 10b5-1 Aktier Resterende aktier Procent
Lave om
Del
Pris
Tran
Værdi
Tilbage
Værdi
2022-05-31 2022-05-26 4 APTX Aptinyx Inc.
Stock Option (Right to Buy)
A - Award 40.000 40.000
2021-09-13 2021-09-09 4 CRVS Corvus Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 15.000 15.000
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Series B-1 Preferred Stock
C - Conversion -79.734 0 -100,00
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Series B-1 Preferred Stock
C - Conversion -171.505 0 -100,00
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Series B-1 Preferred Stock
C - Conversion -114.843 0 -100,00
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Series B-1 Preferred Stock
C - Conversion -88.775 0 -100,00
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Series B-1 Preferred Stock
C - Conversion -299.003 0 -100,00
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Series B-1 Preferred Stock
C - Conversion -309.321 0 -100,00
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Series A-1 Preferred Stock
C - Conversion -935.985 0 -100,00
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Series A-1 Preferred Stock
C - Conversion -2.013.269 0 -100,00
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Series A-1 Preferred Stock
C - Conversion -1.348.119 0 -100,00
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Series A-1 Preferred Stock
C - Conversion -1.042.120 0 -100,00
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Series A-1 Preferred Stock
C - Conversion -3.509.939 0 -100,00
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Series A-1 Preferred Stock
C - Conversion -3.631.066 0 -100,00
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Common Stock
P - Purchase 12.368 256.783 5,06 15,00 185.520 3.851.745
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Common Stock
C - Conversion 244.415 244.415
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Common Stock
P - Purchase 26.604 552.333 5,06 15,00 399.060 8.284.995
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Common Stock
C - Conversion 525.729 525.729
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Common Stock
C - Conversion 352.037 352.037
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Common Stock
C - Conversion 272.131 272.131
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Common Stock
P - Purchase 46.381 962.939 5,06 15,00 695.715 14.444.085
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Common Stock
C - Conversion 916.558 916.558
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Common Stock
P - Purchase 47.981 996.169 5,06 15,00 719.715 14.942.535
2021-08-03 2021-08-02 4 ICVX Icosavax, Inc.
Common Stock
C - Conversion 948.188 948.188
2021-06-16 2021-06-15 4 CRVS Corvus Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 15.000 15.000
2021-06-01 2021-05-27 4 APTX Aptinyx Inc.
Stock Option (Right to Buy)
A - Award 40.000 40.000
2021-01-05 2020-12-31 4 APTX Aptinyx Inc.
Stock Option (Right to Buy)
A - Award 4.496 4.496 2,22 9.999 9.999
2020-10-02 2020-09-30 4 APTX Aptinyx Inc.
Stock Option (Right to Buy)
A - Award 4.623 4.623 2,16 10.000 10.000
2020-07-02 2020-06-30 4 APTX Aptinyx Inc.
Stock Option (Right to Buy)
A - Award 3.735 3.735 2,68 9.999 9.999
2020-06-12 2020-06-09 4 CRVS Corvus Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 15.000 15.000
2020-05-22 2020-05-20 4 APTX Aptinyx Inc.
Stock Option (Right to Buy)
A - Award 40.000 40.000
2020-04-02 2020-03-31 4 APTX Aptinyx Inc.
Stock Option (Right to Buy)
A - Award 7.374 7.374 1,36 9.999 9.999
2020-03-23 2020-03-19 4 CRVS Corvus Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 15.000 15.000
2020-01-03 2019-12-31 4 APTX Aptinyx Inc.
Stock Option (Right to Buy)
A - Award 4.668 4.668 2,14 9.999 9.999
2019-10-02 2019-09-30 4 APTX Aptinyx Inc.
Stock Option (Right to Buy)
A - Award 4.802 4.802 2,08 9.998 9.998
2019-07-02 2019-06-28 4 APTX Aptinyx Inc.
Stock Option (Right to Buy)
A - Award 5.046 5.046 1,98 10.001 10.001
2019-06-24 2019-06-20 4 CRVS Corvus Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 15.000 15.000
2019-05-17 2019-05-15 4 APTX Aptinyx Inc.
Stock Option (Right to Buy)
A - Award 40.000 40.000
2019-04-02 2019-03-29 4 APTX Aptinyx Inc.
Stock Option (Right to Buy)
A - Award 4.123 4.123 2,42 9.998 9.998
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Series B Convertible Preferred Stock
C - Conversion -7.676.955 0 -100,00
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -11.551.579 0 -100,00
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -10.107.719 0 -100,00
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Series B Convertible Preferred Stock
C - Conversion -2.303.087 0 -100,00
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -3.465.474 0 -100,00
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -3.032.316 0 -100,00
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Series B Convertible Preferred Stock
C - Conversion -2.643.505 0 -100,00
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -3.977.704 0 -100,00
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -3.480.521 0 -100,00
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Series B Convertible Preferred Stock
C - Conversion -3.443.798 0 -100,00
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -5.181.913 0 -100,00
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -4.534.213 0 -100,00
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Series B Convertible Preferred Stock
C - Conversion -2.531.884 0 -100,00
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -3.809.747 0 -100,00
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -3.333.558 0 -100,00
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Series B Convertible Preferred Stock
C - Conversion -3.347.072 0 -100,00
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -5.036.369 0 -100,00
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -4.406.861 0 -100,00
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
P - Purchase 52.471 1.115.910 4,93 16,00 839.536 17.854.560
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
C - Conversion 278.290 1.063.439 35,44
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
C - Conversion 418.745 785.149 114,29
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
C - Conversion 366.404 366.404
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
P - Purchase 15.741 334.772 4,93 16,00 251.856 5.356.352
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
C - Conversion 83.487 319.031 35,44
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
C - Conversion 125.623 235.544 114,28
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
C - Conversion 109.921 109.921
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
P - Purchase 18.068 384.255 4,93 16,00 289.088 6.148.080
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
C - Conversion 95.827 366.187 35,44
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
C - Conversion 144.192 270.360 114,29
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
C - Conversion 126.168 126.168
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
P - Purchase 23.538 554.231 4,44 16,00 376.608 8.867.696
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
C - Conversion 124.838 530.693 30,76
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
C - Conversion 187.844 405.855 86,16
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
C - Conversion 164.365 218.011 306,39
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
P - Purchase 17.305 407.470 4,44 16,00 276.880 6.519.520
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
C - Conversion 91.781 390.165 30,76
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
C - Conversion 138.103 298.384 86,16
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
C - Conversion 120.841 160.281 306,39
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
P - Purchase 22.877 538.664 4,44 16,00 366.032 8.618.624
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
C - Conversion 121.331 515.787 30,76
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
C - Conversion 182.568 394.456 86,16
2018-06-26 2018-06-25 4 APTX Aptinyx Inc.
Common Stock
C - Conversion 159.749 211.888 306,39
2018-06-25 2018-06-21 4 CRVS Corvus Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 15.000 15.000
2018-06-20 3 APTX Aptinyx Inc.
Common Stock
1.090.342
2018-06-20 3 APTX Aptinyx Inc.
Common Stock
1.056.604
2018-06-20 3 APTX Aptinyx Inc.
Common Stock
963.279
2018-06-20 3 APTX Aptinyx Inc.
Common Stock
947.305
2018-06-20 3 APTX Aptinyx Inc.
Common Stock
892.690
2018-06-20 3 APTX Aptinyx Inc.
Common Stock
879.991
2018-06-20 3 APTX Aptinyx Inc.
Common Stock
894.197
2018-06-20 3 APTX Aptinyx Inc.
Common Stock
1.090.342
2018-06-20 3 APTX Aptinyx Inc.
Common Stock
1.056.604
2018-06-20 3 APTX Aptinyx Inc.
Common Stock
963.279
2018-06-20 3 APTX Aptinyx Inc.
Common Stock
947.305
2018-06-20 3 APTX Aptinyx Inc.
Common Stock
892.690
2018-06-20 3 APTX Aptinyx Inc.
Common Stock
879.991
2018-06-20 3 APTX Aptinyx Inc.
Common Stock
894.197
2018-06-20 3 APTX Aptinyx Inc.
Common Stock
1.090.342
2018-06-20 3 APTX Aptinyx Inc.
Common Stock
1.056.604
2018-06-20 3 APTX Aptinyx Inc.
Common Stock
963.279
2018-06-20 3 APTX Aptinyx Inc.
Common Stock
947.305
2018-06-20 3 APTX Aptinyx Inc.
Common Stock
892.690
2018-06-20 3 APTX Aptinyx Inc.
Common Stock
879.991
2018-06-20 3 APTX Aptinyx Inc.
Common Stock
894.197
2018-03-13 2018-03-12 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value
P - Purchase 126.806 126.806 8,50 1.077.851 1.077.851
2018-03-13 2018-03-12 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value
P - Purchase 87.668 87.668 8,50 745.178 745.178
2018-03-13 2018-03-12 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value
P - Purchase 67.769 67.769 8,50 576.036 576.036
2018-03-13 2018-03-12 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value
P - Purchase 236.128 236.128 8,50 2.007.088 2.007.088
2018-03-13 2018-03-12 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value
P - Purchase 69.864 69.864 8,50 593.844 593.844
2017-06-09 2017-06-08 4 CRVS Corvus Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 15.000 15.000
2016-06-24 2016-06-22 4 OMED OncoMed Pharmaceuticals Inc
Stock Option (Right to Buy)
A - Award 15.000 15.000
2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Series B Convertible Preferred Stock
C - Conversion -97.746 0 -100,00
2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Series A Convertible Preferred Stock
C - Conversion -583.510 0 -100,00
2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Series B Convertible Preferred Stock
C - Conversion -71.863 0 -100,00
2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Series A Convertible Preferred Stock
C - Conversion -428.998 0 -100,00
2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Series B Convertible Preferred Stock
C - Conversion -95.001 0 -100,00
2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Series A Convertible Preferred Stock
C - Conversion -567.121 0 -100,00
2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Series B Convertible Preferred Stock
C - Conversion -92.278 0 -100,00
2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Series A Convertible Preferred Stock
C - Conversion -550.864 0 -100,00
2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value
P - Purchase 54.777 736.033 8,04 15,00 821.655 11.040.495
2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value
C - Conversion 97.746 681.256 16,75
2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value
C - Conversion 583.510 583.510
2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value
P - Purchase 40.272 541.133 8,04 15,00 604.080 8.116.995
2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value
C - Conversion 71.863 500.861 16,75
2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value
C - Conversion 428.998 428.998
2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value
P - Purchase 53.239 715.361 8,04 15,00 798.585 10.730.415
2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value
C - Conversion 95.001 662.122 16,75
2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value
C - Conversion 567.121 567.121
2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value
P - Purchase 51.712 694.854 8,04 15,00 775.680 10.422.810
2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value
C - Conversion 92.278 643.142 16,75
2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value
C - Conversion 550.864 550.864
2016-03-24 2016-03-22 4 CRVS Corvus Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 30.000 30.000
2015-12-02 2015-11-30 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 14.695 59.567 32,75
2015-12-02 2015-11-30 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 2.939 12.046 32,27
2015-12-02 2015-11-30 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 22.125 90.349 32,43
2015-12-02 2015-11-30 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 7.026 28.691 32,43
2015-12-02 2015-11-30 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 9.205 37.591 32,43
2015-12-02 2015-11-30 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 24.631 82.395 42,64
2015-12-02 2015-11-30 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 2.431 7.294 49,99
2015-12-02 2015-11-30 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 782 2.346 50,00
2015-12-02 2015-11-30 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 1.166 3.498 50,00
2015-12-02 2015-11-30 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 19.666 59.000 50,00
2015-12-02 2015-11-30 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 14.118 42.355 50,00
2015-12-02 2015-11-30 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 18.277 54.833 50,00
2015-12-02 2015-11-30 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 39.017 125.060 45,35
2015-06-23 2015-06-19 4 OMED OncoMed Pharmaceuticals Inc
Stock Option (Right to Buy)
A - Award 15.000 15.000
2015-02-26 2015-02-24 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 17.775 44.872 65,60
2015-02-26 2015-02-24 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 3.555 9.107 64,03
2015-02-26 2015-02-24 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 26.762 68.224 64,55
2015-02-26 2015-02-24 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 8.499 21.665 64,55
2015-02-26 2015-02-24 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 11.135 28.386 64,55
2015-02-26 2015-02-24 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 27.218 57.764 89,10
2015-02-26 2015-02-24 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 2.432 4.863 100,04
2015-02-26 2015-02-24 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 782 1.564 100,00
2015-02-26 2015-02-24 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 1.166 2.332 100,00
2015-02-26 2015-02-24 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 19.667 39.334 100,00
2015-02-26 2015-02-24 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 14.119 28.237 100,01
2015-02-26 2015-02-24 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 18.278 36.556 100,00
2015-02-26 2015-02-24 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 43.022 86.043 100,00
2015-01-13 2014-08-08 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 4.575 9.322 96,38
2015-01-13 2014-08-08 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 980 1.997 96,36
2015-01-13 2014-08-08 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 1.634 3.329 96,40
2015-01-13 2014-08-08 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 7.215 14.701 96,38
2015-01-13 2014-08-08 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 2.291 4.668 96,38
2015-01-13 2014-08-08 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 3.002 6.117 96,37
2015-01-13 2014-05-09 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 4.747 4.747
2015-01-13 2014-05-09 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 1.017 1.017
2015-01-13 2014-05-09 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 1.695 1.695
2015-01-13 2014-05-09 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 7.486 7.486
2015-01-13 2014-05-09 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 2.377 2.377
2015-01-13 2014-05-09 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 3.115 3.115
2015-01-13 2015-01-09 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 17.775 27.097 190,68
2015-01-13 2015-01-09 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 3.555 5.552 178,02
2015-01-13 2015-01-09 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 26.761 41.462 182,04
2015-01-13 2015-01-09 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 8.498 13.166 182,05
2015-01-13 2015-01-09 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 11.134 17.251 182,02
2015-01-13 2015-01-09 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 27.217 30.546 817,57
2015-01-13 2015-01-09 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 2.431 2.431
2015-01-13 2015-01-09 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 782 782
2015-01-13 2015-01-09 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 1.166 1.166
2015-01-13 2015-01-09 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 19.667 19.667
2015-01-13 2015-01-09 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 14.118 14.118
2015-01-13 2015-01-09 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 18.278 18.278
2015-01-13 2015-01-09 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
J - Other 43.021 43.021
2014-06-20 2014-06-18 4 OMED OncoMed Pharmaceuticals Inc
Stock Option (Right to Buy)
A - Award 15.000 15.000
2013-07-23 2013-07-23 4 OMED OncoMed Pharmaceuticals Inc
Series B-1 Preferred Stock
C - Conversion -322.142 0 -100,00
2013-07-23 2013-07-23 4 OMED OncoMed Pharmaceuticals Inc
Series B-1 Preferred Stock
C - Conversion -348.652 0 -100,00
2013-07-23 2013-07-23 4 OMED OncoMed Pharmaceuticals Inc
Series B Preferred Stock
C - Conversion -270.811 0 -100,00
2013-07-23 2013-07-23 4 OMED OncoMed Pharmaceuticals Inc
Series B Preferred Stock
C - Conversion -293.098 0 -100,00
2013-07-23 2013-07-23 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
C - Conversion 322.142 592.953 118,95
2013-07-23 2013-07-23 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
C - Conversion 270.811 270.811
2013-07-23 2013-07-23 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
C - Conversion 348.652 641.750 118,95
2013-07-23 2013-07-23 4 OMED OncoMed Pharmaceuticals Inc
Common Stock
C - Conversion 293.098 293.098
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)